Generated by AI
Mentari Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapies for migraine prevention. Its pipeline centers on biological pathways involved in migraine, including pituitary adenylate cyclase-activating polypeptide (PACAP) and calcitonin gene-related peptide (CGRP). The company’s lead programs include MT-001, an anti-PACAP monoclonal antibody designed for subcutaneous administration, and MT-002, a bispecific antibody intended to inhibit both PACAP and CGRP signaling. These programs address patients who may not respond adequately to existing migraine-prevention approaches and reflect the company’s emphasis on targeted, mechanism-based treatment development. Mentari operates within the biotechnology and specialty pharmaceutical sectors, with activities spanning drug discovery, preclinical research, clinical development, and the advancement of biologic therapies toward potential commercialization. Through its focused pipeline, the company participates in the global healthcare market for neurological disorders and contributes to the development of preventive treatment options for people living with migraine.
Website500 West Georgia Street
Vancouver, BC, V6B 0M3
Canada
The latest articles about INM.
Summary of Oct 27's posts. Generated by AI.
Summary of Jul 22's posts. Generated by AI.
Summary of Sep 12's posts. Generated by AI.
Summary of Jul 22's posts. Generated by AI.
Investors talking about INM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.